Sponsor

Fakultni Nemocnice Ostrava

Czechia 17. Listopadu 1790/5, Poruba, 708 00 Ostrava, Czechia

About the sponsor

Clinical research in relapsing-remitting multiple sclerosis and primary progressive multiple sclerosis with interest in ocrelizumab therapeutic monitoring and the relationship between serum drug concentrations and clinical markers.

Ocrelizumab serum concentration monitoring
Personalized pharmacotherapy
Clinical and paraclinical indicators

The research activity in this area centers on treatment individualization in neuroimmunology and the optimization of disease-modifying therapy.

About Specializations

Fakultni Nemocnice Ostrava runs clinical trials in conditions such as Multiple sclerosis, Heart failure with reduced ejection fraction, Lung assist device therapy, Femoral neck fracture, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Quick filters

4 clinical trials

Multiple sclerosis

Recruiting

Study on Monitoring Ocrelizumab Levels for Personalized Treatment in Patients with Relapsing-Remitting and Primary Progressive Multiple Sclerosis

Registered drugNo placebo

Study on Monitoring Ocrelizumab Levels for Personalized Treatment in Patients with Relapsing-Remitting and Primary Progressive Multiple Sclerosis

Registered drugNo placebo

Czechia

Participants:18–64 years · 65+ years
Substances:Ocrelizumab
Sponsor:Fakultni Nemocnice Ostrava

Contact Research Centre

Heart failure with reduced ejection fraction

Recruiting

Study on Optimizing Treatment for Chronic Heart Failure with Reduced Ejection Fraction Using Nebivolol and a Drug Combination

Registered drugNo placebo

Study on Optimizing Treatment for Chronic Heart Failure with Reduced Ejection Fraction Using Nebivolol and a Drug Combination

Registered drugNo placebo

Czechia

Participants:18–64 years · 65+ years
Substances:Bisoprolol Fumarate
Sponsor:Fakultni Nemocnice Ostrava

Contact Research Centre

Lung assist device therapy

Not yet recruiting

Comparing low-dose and standard-dose argatroban or enoxaparin to prevent blood clots in patients with heart or lung failure receiving extracorporeal membrane oxygenation.

Registered drugNo placebo